[Catatonia, malignant neuroleptic syndrome and myositis ossificans].
Lethal catatonia and the malignant neuroleptic syndrome represent two potentially fatal disorders that require different therapeutic regimens. Clinical differentiation is considered difficult because of a number of similarities with respect to mode of onset, signs and symptoms, and outcome. Recent observations emphasizing similarities between the two disorders, however, suggest that catatonia and the malignant neuroleptic syndrome may not represent separate diagnostic entities. Instead, the malignant neuroleptic syndrome has been hypothesized to be a neuroleptic-aggravated form of catatonia. In the present paper, we report the case of a 22-year-old male who developed different forms of malignant neuroleptic syndromes subsequent to a catatonic episode and overlapping it. In addition, the course was complicated by the occurrence of heterotopic calcification within skeletal muscles. The clinical value of diagnostic criteria that help distinguish catatonia from neuroleptic malignant syndrome and their therapeutic consequences are discussed.
Topka
H
H
Neurologische Klinik, Universität, Tübingen.
Buchkremer
G
G
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002389:Catatonia / Q000139:chemically induced* / Q000175:diagnosis; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009221:Myositis Ossificans / Q000139:chemically induced* / Q000175:diagnosis; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis*; D009460:Neurologic Examination / Q000187:drug effects; D012560:Schizophrenia, Catatonic / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology
D014150:Antipsychotic Agents